Abstract:Non‐alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver damage directly related to diabetes, metabolic syndrome, and obesity. The (Pro)renin receptor (PRR) in the liver recently has been shown to play an important role in hepatic steatosis. In this study, we test our hypothesis that PRR antagonist, PRO20, reduces hepatic steatosis and fibrosis. Wild‐type mice in C57Bl/6J background (n=9‐10/group) were fed with either HFD (60% calories from fat) or normal fat chow (NFD, 10% calories from fat) with matching calories for 6 weeks. Methionine choline deficient (MCD) diet was used to study fibrosis development in C57BL/6J mice for 8 weeks. Two weeks following respective diet modifications, mice were implanted with a subcutaneous osmotic pump (4 or 6 week release model) containing either PRO20 (700ug/kg/d) or saline. Liver tissues were processed for Oil Red O (ORO), H&E, and Masson’s trichrome histology staining for lipid and collagen accumulation. The presence of lipids, indicative of steatosis, was quantified using ImageJ/FIJI software and presented as % of ORO staining to the total area. We found that 6 weeks of HFD (15.90 ± 1.49 %) induced a significant elevation on liver ORO staining compared with the liver from mice fed with NFD (3.60 ± 1.61 %, p<0.0001). More importantly, PRO20 treatment (9.91 ± 1.46 %; p = 0.001) significantly reduced the ORO staining in mice treated with HFD. Hepatic triglyceride concentrations were quantified with colorimetric assay and shown to be significantly lowered in PRO20 treated mice (2.110 ± 0.6175) compared with scramble peptide treated (6.470 ± 0.3553, p<0.0001) mice under HFD. Collagen area was also found to be reduced in MCD PRO20 (4.970 ± 0.9096 %) treated mice compared with the control mice (8.901 ± 0.2782, p = 0.0033). Moreover, PRO20 treatment (258 ± 53.12 U/L) decreased liver ALT levels in MCD‐fed PRO20 mice compared with the control mice (682 ± 116.4 U/L). De novo lipogenesis genes thought to contribute to the development and progression of NAFLD were evaluated by real‐time PCR and presented as fold‐change expression normalized to β‐actin. The glycerol‐3‐phosphate acetyltransferase 3 (GPAT3) (1.835 ± 0.1798, p = 0.0183) expression was found to be downregulated in the livers of HFD PRO20 treated mice. Our findings indicate that PRO20 reduces HFD‐induced hepatic steatosis and MCD‐induced liver fibrosis and liver dysfunction. We conclude that PRR antagonism using PRO20 might be an effective therapeutic approach for treatment of NAFLD.

Expression and activity of prolyl endopeptidase in the liver tissues of mice with non-alcoholic fatty liver disease

Expressions of Key Regulatory Genes of the Lipid Metabolism in Livers During the Development of Rat Non-alcoholic Fatty Liver Disease

Prolyl Endopeptidase Gene Disruption Attenuates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice by Improving Hepatic Steatosis and Inflammation

Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet

Prolyl Endopeptidase Disruption Reduces Hepatic Inflammation and Oxidative Stress in Methionine-Choline-deficient Diet-Induced Steatohepatitis.

Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease.

Lactobacillus Casei YRL577 Combined with Plant Extracts Reduce Markers of Non-Alcoholic Fatty Liver Disease in Mice

Identification of gene expression patterns in rat model of nonalcoholic fatty liver disease

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Study on Relationship Between Fat-Rich Diet-Induced Nonalcoholic Fatty Liver Disease and Endoplasmic Reticulum Stress in Rats

[Effect of Soothing Liver and Invigorating Spleen Recipes on SREBP-1c Mrna and Protein Expression in Hepatic Tissues of Rats with Non-Alcoholic Fatty Liver Disease].

Role of Nrf2 on the mechanism of nonalcoholic fatty liver disease in mice

Comparative Proteomic Analysis of Liver Tissues and Serum in <i>db</i>/<i>db</i> Mice

Expression of Tissue-Type Plasminogen and Plasminogen Activator Inhibitor-1 in Liver of Rats with Nonalcoholic Fatty Liver Disease

Overexpression of Peroxisome Proliferator-Activated Receptor Gamma in Liver of Rats with Non-Alcoholic Fatty Liver Disease Chronically Fed with High-Fat Diet

The (pro)renin receptor antagonist, PRO20, attenuates high fat diet induced hepatic steatosis and fibrosis in non‐alcoholic fatty liver disease (NAFLD)

PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway

Comparative Proteomic Analysis of Liver Tissues and Serum in Db/db Mice

Effect of High Fat on Expressions of Hepatic NLRP3 Inflammasome-related Genes in vivo and in vitro

The Expression Change of COX and CPT in Different Stages of Non-Alcoholic Fatty Liver Disease

Effects of 15-Deoxy-prostaglandin J_2on Expression of Proliferator-Activated Receptorγ,tumor Necrosis Factor-Αand Interleukin-6In Liver Tissue of Rats with Nonalcoholic Fatty Liver Disease